Guarantees of borrowings by two Sinopharm Group Beijing companies
First written in FY2024-Q2. 2 of 7 entries say "Mitigated", first in FY2025-H1. Latest entry: FY2026.
Medipal Holdings moved to the "Worse" side of this theme in 2026, 4 years after the typical company in this theme (2022).
The whole theme swung hardest in 2017: 12 of 49 companies on the "Worse" side.
26 other companies' latest entry also says "Worsened".
- FY2026WorsenedAnnual report
「国薬控股北京天星普信生物医薬有限公司 ¥1,848 million 国薬控股北京華鴻有限公司 ¥1,386 million Total ¥3,235 million」
Borrowing guarantees for the two 国薬控股北京 companies increased from none disclosed at the end of the previous fiscal year to a total of ¥3,235 million at the end of the current fiscal year. - FY2026-H1WorsenedAnnual report
「国薬控股北京天星普信生物医薬有限公司 ¥1,670 million 国薬控股北京華鴻有限公司 ¥1,252 million Total ¥2,923 million」
At the end of the interim consolidated fiscal period, total borrowing guarantees for the two 国薬控股北京 companies amounted to ¥2,923 million. The credit exposure represented by guarantee obligations is specifically disclosed as of the end of the period. - FY2025MitigatedAnnual report
「国薬控股北京天星普信生物医薬有限公司 ¥1,666 million — million」
The borrowing guarantee for 国薬控股北京天星普信生物医薬有限公司 decreased from ¥1,666 million at the end of the previous consolidated fiscal year to “-” at the end of the current consolidated fiscal year. - FY2025-H1MitigatedAnnual report
「Guarantees have been provided for the borrowings listed below. Previous consolidated fiscal year (31 March 2024): 国薬控股北京天星普信生物医薬有限公司: ¥1,666 million Current interim consolidated fiscal year (30 September 2024): — million」
The guarantee for borrowings of 国薬控股北京天星普信生物医薬有限公司 was listed as “—” at the end of the current interim consolidated fiscal year, compared with ¥1,666 million at the end of the previous consolidated fiscal year. - FY2024Update to Guarantee AmountAnnual report
「Guarantees have been provided for the borrowings listed below. Previous consolidated fiscal year (31 March 2023): — million Current consolidated fiscal year (31 March 2024): 国薬控股北京天星普信生物医薬有限公司: ¥1,666 million」
A guarantee amount of ¥1,666 million was disclosed for 国薬控股北京天星普信生物医薬有限公司. This increased from ¥1,594 million in the previous disclosure, while the guarantee for 国薬控股北京華鴻有限公司 is not listed in the table for the current fiscal year. - FY2024-Q3Change in Disclosed Guaranteed BorrowingsAnnual report
「Guarantees have been provided for the borrowings listed below. Previous consolidated fiscal year (31 March 2023): — million Third quarter of the current consolidated fiscal year (31 December 2023): 国薬控股北京天星普信生物医薬有限公司: ¥1,594 million」
The previous filing disclosed total guarantees of ¥2,864 million for 国薬控股北京天星普信生物医薬有限公司 and 国薬控股北京華鴻有限公司, whereas this filing lists ¥1,594 million for 国薬控股北京天星普信生物医薬有限公司. The text does not establish whether the other guarantee has ceased to exist. - FY2024-Q2First statedAnnual report
「Guarantees have been provided for the borrowings listed below. 国薬控股北京天星普信生物医薬有限公司: ¥1,636 million 国薬控股北京華鴻有限公司: ¥1,227 million Total: ¥2,864 million」
Guarantee obligations totaling ¥2,864 million were disclosed for borrowings of 国薬控股北京天星普信生物医薬有限公司 and 国薬控股北京華鴻有限公司. The text does not state that any default or other failure to perform occurred.